REG - Eco Animal Health Gp - ECOVAXXIN® MG favourable USDA safety assessment

ECO Animal HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260311:nRSK1219Wa&default-theme=true

RNS Number : 1219W  Eco Animal Health Group PLC  11 March 2026

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

 ECOVAXXIN® MG receives favourable USDA safety assessment

Assessment represents a significant milestone towards US marketing
authorisation

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that the United States Department of
Agriculture (USDA) has delivered a favourable safety assessment of
ECOVAXXIN® MG, the Company's live poultry vaccine targeting Mycoplasma
gallisepticum.

 

The USDA's review and acceptance of the Company's ECOVAXXIN® MG safety data
represents an important step towards securing marketing authorisation for the
vaccine in the United States. The comprehensive risk assessment confirms that
ECO meets the USDA's rigorous safety standards, with final regulatory
submission for ECOVAXXIN® MG currently anticipated in late 2027.

 

As part of the US registration requirements, ECOVAXXIN® MG was demonstrated
to be safe not only for the target species (chickens) but also for
non‑target avian species including turkeys and quails. Importantly, the
strain did not revert or increase in virulence after passage through chickens,
confirming its stability.

 

Mycoplasma gallisepticum is a bacterial pathogen responsible for chronic
respiratory disease in chickens and infectious sinusitis in turkeys. The live
strain of the bacteria used for ECOVAXXIN® MG is a naturally attenuated
isolate shown to be safe for young chicks.

 

David Hallas, Chief Executive Officer of ECO Animal Health, said: "ECO is
building a robust product portfolio to provide the poultry industry with safe
and effective new vaccines against Mycoplasma infection. ECOVAXXIN® MS
represented the Company's first step toward expanding its range of innovative
vaccines across priority markets, with commercial launch expected later in
2026.

 

"ECOVAXXIN® MG's strong safety profile builds further positive momentum in
our R&D pipeline. The favourable risk assessment underlines that the
product meets the USDA's high safety benchmarks and represents a significant
milestone towards US marketing authorisation."

 

-Ends-

 

Contacts

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Samed Ethemi

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGMFRGFGVZM



            Copyright 2019 Regulatory News Service, all rights reserved